showed that, by secreting Interleukin-8 (IL-8), the TAMs activate Src/STAT3/ERK1/2-mediated EGFR signaling in BC cells, contributing to the resistance of HER2-positive BC to the small drug HER2 inhibitor lapatinib (71). This evidence concerns the gene STAT3 and breast cancer.